Company: IMNN
Filing Date: 2025-05-20
Form Type: 8-K
Source: 0001641172-25-011601
Chunk: 1

Company: Imunon, Inc.
Filing Date: 2025-05-20
Form: 8-K
Item: Item 3.01
Chunk 1
---
.01(a) of Form 8-K that the
Company publicly disclose the receipt of the deficiency notice within four (4) business days after the date of the deficiency letter.

The
Notice is unrelated to the Company’s previously disclosed deficiency relating to Nasdaq’s minimum bid price requirement,
as previously disclosed in the Company’s Current Report on Form 8-K

Except
for the factual statements made herein, information contained in this report consists of forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that are difficult to predict.
Words such as “will,” “believes,” “intends,” “expects,” “plans,” and similar
expressions, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not
forward-looking. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially
from those contained in such statements. For example, there can be no assurance that the Company will meet the bid price requirement
or the Minimum Stockholders’ Equity Requirement during any compliance period or in the future, or otherwise meet Nasdaq compliance
standards, or that Nasdaq will grant the Company any relief from delisting as necessary or that the Company can ultimately meet applicable
Nasdaq requirements for any such relief. The forward-looking statements contained in this report speak only as of the date of this report
and the Company undertakes no obligation to publicly update any forward-looking statements to reflect changes in information, events
or circumstances after the date of this report, unless required by law.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                           IMUNON, INC.                                               
  Dated: May 20, 2025      By:               /s/ Susan Eylward                        
                                             Susan Eylward                            
                                             General Counsel and Corporate Secretary